LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.

  LumiraDx Second Quarter 2022 Financial Results Conference Call

Date: Thursday, August 18, 2022
Time: 8:00 AM Eastern Time   
Live Call/Webcast:    Register to join by phone here.
https://investors.lumiradx.com/news-and-events/investor-calendar 

A replay of the webcast will be available on the Investor’s section of the company’s website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.

About LumiraDx
LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
Further information on LumiraDx and the LumiraDx Platform is available at www.lumiradx.com 

Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com

Staff

Recent Posts

Defence’s Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…

1 hour ago

Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement

Proposed business combination to create a North American technology company with an AI-driven fintech marketplace.…

5 hours ago

Dr. Ji Han’s NY Spine Care Offers Cutting-Edge Interventional Pain Management

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Chronic pain affects millions of…

8 hours ago

FendX Technologies Announces Second Closing of Non-Brokered Private Placement and Announces Further Upsizing to $2 million

Oakville, Ontario--(Newsfile Corp. - March 25, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

11 hours ago

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30…

11 hours ago

Brüush Receives Additional Delisting Notification to Address at Hearing

VANCOUVER, BC / ACCESSWIRE / March 25, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the…

11 hours ago